Project Grant K99HL179400
Award Date
8/1/25
Completion Date
5/31/27
Dollars Obligated
$131K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to generate human induced pluripotent stem cell (iPSC) models of type 2 diabetic cardiomyopathy (T2DCM) and assess the metabolic mechanisms and protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors. The total award is $511,864 with a project period from Sep 6, 2024 to Mar 31, 2026. The research will be...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $159,512 to The Leland Stanford Junior University to investigate strategies for mitigating cardiac fibrosis, a key contributor to dilated cardiomyopathy (DCM). The research aims to validate two candidate compounds identified in a prior drug screen, CGS15943 and AM404, using advanced techniques like 3D cardiac organoids and a mouse DCM...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512 to The Leland Stanford Junior University to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy (DCM). The research utilizes induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) carrying DCM mutations to study the cellular and molecular mechanisms by which impaired proteostasis leads to cardiac dysfunction in...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $259,464 to The Leland Stanford Junior University to conduct research on "Mitochondrial Therapy in Conjunction with Guideline Directed Medical Therapy in Cardiomyopathy". The primary objectives are to: 1) Determine the mechanism of the protective effects of mitochondria-rich extracellular vesicles (M-EVs) in combination with guideline-directed...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $125,568 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Stanford University. The grant supports research to explore the molecular mechanisms governing the import and regulation of NAD+ within the mitochondrial matrix. This work aims to elucidate how mitochondria maintain adequate NAD+ levels and how this process may become dysregulated in heart failure, a major global health issue. The...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $654,530 to the University of Utah to investigate the role of the serine-threonine kinase SGK1 in regulating cardiac function and metabolism in cardiometabolic heart failure with preserved ejection fraction (cMet HFPEF). The 4-year project aims to determine how cardiac-specific SGK1 signaling, particularly through its phosphorylation of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel, injectable biomaterial hydrogel to enable sustained delivery of the therapeutic protein neuregulin-1 (NRG1) to the myocardium for the treatment of myocardial infarction (MI). The $769,789 award to The Leland Stanford Junior University will support a 4-year research project to design and evaluate the...
This Project Grant award of $1,102,957 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The Leland Stanford Junior University will fund research to investigate the relationship between cancer and cardiovascular disease. The project aims to: 1) use epidemiological and genetic approaches to map causal links and shared genetic factors between the two disease states; 2) leverage advanced mouse models to prove that cancer can directly promote...
The federal Project Grant award of $100,050.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the potential role of cardiometabolic drugs, such as glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2I), as well as the repurposing of metformin and bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research...